Tirzepatide: structure, nomenclature and handling

Tirzepatide is built on the GIP peptide backbone rather than the GLP-1 backbone, which is the first thing that distinguishes it from most analogues in this class. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 are both incretins and both members of the glucagon superfamily, but they are distinct sequences, and tirzepatide's 39 residues follow the former more closely.

The sequence is engineered so that it is characterized against both the GIP receptor and the GLP-1 receptor. That dual engagement is a structural property arising from deliberate substitutions at positions that determine selectivity between the two receptors, and it is why the compound is catalogued as a dual-receptor agonist rather than a GIP analogue with incidental cross-reactivity.

Two non-proteinogenic alpha-aminoisobutyric acid residues appear in the sequence, at positions 2 and 13. As in other engineered incretins, AIB introduces steric bulk that obstructs enzymatic cleavage — position 2 in particular is the dipeptidyl peptidase-4 site that limits the native peptide's persistence.

A C20 fatty diacid is attached through a linker at lysine 20. The chain is longer than the C18 used in some other analogues in the class, and as with those, it promotes reversible albumin binding. The lipid governs persistence rather than receptor engagement.

Tirzepatide appears in the literature under the development code LY3298176. As with other compounds in this family the development code remains in wide use in published work, so searches should cover both it and the generic name.

The generic name carries the -tide suffix used across peptide therapeutics generally, rather than the -glutide stem specific to glucagon-family analogues. That difference is itself informative: it reflects that tirzepatide is not built on the GLP-1 sequence.

In the HEEZ catalogue the title carries the shorthand GLP-2 TZ. This is vendor listing shorthand — TZ for tirzepatide — and it is not a reference to the glucagon-like peptide-2 receptor. Tirzepatide is not characterized against GLP-2, and reading the code as a receptor claim would be a mistake.

Identity is confirmed by mass spectrometry against the theoretical mass of the 39-residue modified sequence. The two AIB residues and the C20 diacid each contribute defined increments, so the observed mass distinguishes fully modified material from a peptide missing one of them.

Purity is measured by high-performance liquid chromatography. In a 39-residue synthetic peptide the most informative impurities are deletion sequences — where a residue failed to couple — and material acylated at the wrong lysine. These can elute close to the main peak, which is why the chromatogram is worth inspecting rather than reading the headline figure alone.

Receptor characterization, where reported, is performed in cell-free or cell-based in vitro systems expressing the receptor of interest, and it is at that level that the dual GIP and GLP-1 profile is defined. These are biochemical properties of the isolated molecule.

HEEZ Research supplies tirzepatide in one format: a 10 mg lyophilized vial. There is no alternative strength in the current catalogue.

The material is freeze-dried, leaving the peptide as a solid. This is markedly more stable than solution and tolerates ambient temperature in transit, which is why no cold chain is required for shipping.

At 39 residues plus a C20 chain, tirzepatide is a comparatively heavy molecule, so 10 mg represents fewer molar units than the same mass of a short peptide. Where a protocol is specified in molar terms the molecular weight from the certificate is the figure needed.

The relationship is mass over volume. A 10 mg tirzepatide vial reconstituted with 1 ml gives 10 mg per ml; 2 ml gives 5 mg per ml; 4 ml gives 2.5 mg per ml.

Bacteriostatic water — sterile water with 0.9% benzyl alcohol — is the standard diluent where the vial will be entered more than once. Preservative-free sterile water is used for single-entry work.

peptcalc.com converts a vial mass and a target concentration into a diluent volume directly, and covers molar concentrations where the molecular weight is supplied. Doing the arithmetic explicitly rather than by estimate matters because every downstream dilution inherits the error.

Add diluent gently down the vial wall rather than onto the cake, and swirl rather than shake. Long acylated peptides are among the more aggregation-prone materials in a peptide catalogue.

Sealed lyophilized tirzepatide is ambient-stable through transit, so no insulated packaging or ice packs are used in shipping. On receipt it is refrigerated and kept away from light.

Reconstituted tirzepatide is refrigerated and used inside the window the receiving facility specifies. Freeze-thaw cycling is avoided; each cycle risks aggregation and loss of intact material.

As with other acylated analogues, the lipid modification helps in biological media but does nothing for physical stability in storage. Aggregation, oxidation and surface adsorption remain the routes that matter, and normal peptide handling addresses them.

The certificate documents what an independent facility measured for one batch. Check first that its lot number matches the vial, because a certificate for another lot describes different material however similar the specification.

Identity is reported as observed versus theoretical mass. For tirzepatide the theoretical figure includes both AIB residues and the C20 diacid, so a mass matching an unmodified GIP fragment would indicate a different compound entirely.

Purity is the HPLC main-peak area as a percentage, with the chromatogram supporting it. Peptide content, where reported separately, accounts for counter-ions and residual water and determines how much peptide a nominal 10 mg actually contains.